| 标题 |
A randomized, open-label, blank-controlled, multi-center clinical study for Lian-Hua Qing-Ke Tablets in the treatment of severe novel coronavirus pneumonia
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 | INTERVENTION: Experimental group:Routine treatment + Lian‐Hua Qing‐Ke Tablets;Control group:Conventional treatment; CONDITION: Novel Coronavirus Pneumonia (COVID‐19) PRIMARY OUTCOME: The primary endpoint is time to clinical improvement (censored at Day 28), defined as the time (in days) from randomization of study treatment (remdesivir or placebo) until a decline of two categories on a six‐category ordinal scale of clinical status or live discharge; |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
v0id
Nole
DW
xing_xing
凌凌
cdercder
学术文献互助
DOC_XIONG
舒适的如萱
潇洒的惋清
水煮电吹风
欧克
OK
MchemG
鲤鱼灵寒
七听
铁锤牛马版
唠叨的大门
殷勤的紫槐
皖公网安备34019202002308
